Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 7/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4128106 | 0.85 | CHRM3 (0.50) | CHRM3CHRM2CHRM1CYP2C19CYP1A2 | |
| SCHEMBL5099633 | 0.85 | CHRM3 (0.50) | CHRM3CHRM2CHRM1CYP2C19CYP1A2 | |
| SCHEMBL4618410 | 0.84 | CHRM3 (0.44) | CHRM3OPRM1 | |
| SCHEMBL5099182 | 0.84 | CHRM3 (0.51) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL4619567 | 0.84 | CHRM3 (0.51) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL4142742 | 0.84 | CHRM3 (0.51) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL4620525 | 0.82 | CHRM3 (0.52) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL4143564 | 0.82 | CHRM3 (0.52) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL4619313 | 0.82 | KEAP1 (0.49) | CHRM3CHRM2CHRM1CYP2C19CYP1A2 | |
| SCHEMBL4886779 | 0.80 | CHRM3 (0.52) | CHRM3CHRM2CHRM1KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-25 | — | — | US | claimed |
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.